Route, origin & valence matter: towards sophisticated next-generation vaccines to cope with the COVID-19 pandemic

doi:10.1038/s41392-022-01053-4

Comment

. 2022 Jun 15;7(1):188.

doi: 10.1038/s41392-022-01053-4.

Route, origin & valence matter: towards sophisticated next-generation vaccines to cope with the COVID-19 pandemic

Julia Volckmar^{1

2}, Lars Melcher², Dunja Bruder^{3

4}

Affiliations

¹ Infection Immunology Group, Institute of Medical Microbiology, Infection Prevention and Control, Health Campus Immunology, Infectiology and Inflammation, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
² Immune Regulation Group, Helmholtz Centre for Infection Research, Braunschweig, Germany.
³ Infection Immunology Group, Institute of Medical Microbiology, Infection Prevention and Control, Health Campus Immunology, Infectiology and Inflammation, Otto-von-Guericke University Magdeburg, Magdeburg, Germany. dunja.bruder@med.ovgu.de.
⁴ Immune Regulation Group, Helmholtz Centre for Infection Research, Braunschweig, Germany. dunja.bruder@med.ovgu.de.

PMID: 35705533
PMCID: PMC9199476
DOI: 10.1038/s41392-022-01053-4

Comment

Route, origin & valence matter: towards sophisticated next-generation vaccines to cope with the COVID-19 pandemic

Julia Volckmar et al. Signal Transduct Target Ther. 2022.

. 2022 Jun 15;7(1):188.

doi: 10.1038/s41392-022-01053-4.

Authors

Julia Volckmar^{1

2}, Lars Melcher², Dunja Bruder^{3

4}

Affiliations

¹ Infection Immunology Group, Institute of Medical Microbiology, Infection Prevention and Control, Health Campus Immunology, Infectiology and Inflammation, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
² Immune Regulation Group, Helmholtz Centre for Infection Research, Braunschweig, Germany.
³ Infection Immunology Group, Institute of Medical Microbiology, Infection Prevention and Control, Health Campus Immunology, Infectiology and Inflammation, Otto-von-Guericke University Magdeburg, Magdeburg, Germany. dunja.bruder@med.ovgu.de.
⁴ Immune Regulation Group, Helmholtz Centre for Infection Research, Braunschweig, Germany. dunja.bruder@med.ovgu.de.

PMID: 35705533
PMCID: PMC9199476
DOI: 10.1038/s41392-022-01053-4

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

**Fig. 1**
Mucosal immunization with a trivalent ChAd-vectored vaccine induces superior protection against ancestral SARS-CoV-2 and variants of concern. a Three different SARS-CoV-2 antigen domains (S1 Spike Protein (S1), nucleocapsid (N), RNA-dependent RNA polymerase (RdRp)) were cloned into either human (Tri:HuAd) or chimpanzee (Tri:ChAd) adenoviral vectors. BALB/c mice were immunized either intranasal (i.n.) or intramuscular (i.m.) prior to lethal SARS-CoV-2 challenge. b Results of the comparative analyses utilizing both the two different vector platforms and routes of application (i.n. vs. i.m.). Mucosal immunization (i.n.) with the Tri:ChAd vaccine induced overall superior immune responses: increased production of systemic and local IgG and IgA antibodies, markedly enhanced antibody neutralization capacity, a strong induction of multifunctional CD8⁺ T cell responses as well as the strong activation of T_RM and TII. I.n. vaccinated mice infected with an otherwise lethal dose of SARS-CoV-2 showed no body weight loss and a significant decrease of viral burden. c Schematic representation of the three different chimpanzee adenoviral constructs: the trivalent (S1, N, RdRp), bivalent (N, RdRp) and monovalent (S1) vaccines. Mucosal delivery of the trivalent vaccine exhibits highest protective efficacy against SARS-CoV-2 and varianst of concern (VOC) indicated by prevention of morbidity (body weight loss) and a significant decrease in viral burden compared to mice that received the bivalent or monovalent vaccines. d The optimal vaccination strategy against both SARS-CoV-2 and VOC was proven to be an intranasal application of a trivalent vaccine using the chimpanzee adenoviral vector platform. Created with BioRender.com

See this image and copyright information in PMC

Comment on

Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
Afkhami S, D'Agostino MR, Zhang A, Stacey HD, Marzok A, Kang A, Singh R, Bavananthasivam J, Ye G, Luo X, Wang F, Ang JC, Zganiacz A, Sankar U, Kazhdan N, Koenig JFE, Phelps A, Gameiro SF, Tang S, Jordana M, Wan Y, Mossman KL, Jeyanathan M, Gillgrass A, Medina MFC, Smaill F, Lichty BD, Miller MS, Xing Z. Afkhami S, et al. Cell. 2022 Mar 3;185(5):896-915.e19. doi: 10.1016/j.cell.2022.02.005. Epub 2022 Feb 9. Cell. 2022. PMID: 35180381 Free PMC article.

References

1. Afkhami S, et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 2022;185:896–915. doi: 10.1016/j.cell.2022.02.005. - DOI - PMC - PubMed
1. He, Q. et al. COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations. Front. Immunol.12, 669339 (2021). - PMC - PubMed
1. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin. Microbiol. Infect. 2022;28:202–221. doi: 10.1016/j.cmi.2021.10.005. - DOI - PMC - PubMed
1. Bricker, T. L. et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 36, 109400 (2021). - PMC - PubMed
1. Van Doremalen, N. et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci. Transl. Med., 10.1126/scitranslmed.abh0755 (2021). - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Afkhami S, et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 2022;185:896–915. doi: 10.1016/j.cell.2022.02.005. - DOI - PMC - PubMed

[2] Afkhami S, et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 2022;185:896–915. doi: 10.1016/j.cell.2022.02.005. - DOI - PMC - PubMed

[3] He, Q. et al. COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations. Front. Immunol.12, 669339 (2021). - PMC - PubMed

[4] He, Q. et al. COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations. Front. Immunol.12, 669339 (2021). - PMC - PubMed

[5] Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin. Microbiol. Infect. 2022;28:202–221. doi: 10.1016/j.cmi.2021.10.005. - DOI - PMC - PubMed

[6] Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin. Microbiol. Infect. 2022;28:202–221. doi: 10.1016/j.cmi.2021.10.005. - DOI - PMC - PubMed

[7] Bricker, T. L. et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 36, 109400 (2021). - PMC - PubMed

[8] Bricker, T. L. et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 36, 109400 (2021). - PMC - PubMed

[9] Van Doremalen, N. et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci. Transl. Med., 10.1126/scitranslmed.abh0755 (2021). - PMC - PubMed

[10] Van Doremalen, N. et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci. Transl. Med., 10.1126/scitranslmed.abh0755 (2021). - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Route, origin & valence matter: towards sophisticated next-generation vaccines to cope with the COVID-19 pandemic

Affiliations

Route, origin & valence matter: towards sophisticated next-generation vaccines to cope with the COVID-19 pandemic

Authors

Affiliations

Conflict of interest statement

Figures

Comment on

Similar articles

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical